Phase 4
N=34
Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns
Depression
Bottom Line
View on ClinicalTrials.gov: NCT02078180 ↗Enrolled (actual)
34
Serious AEs
0.0%
Results posted
Oct 2017
Primary outcome: Primary: Comparision of the Buproprion Area Under the Concentration Time Curve (AUC) From Time 0 to 96 Hours by Type of Formulation and Dosage — 469; 667; 706; 1002 h*nanogram/milliliter
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- generic bupropion (Drug)
- Age
- Adult · 25+ yrs
- Sex
- All
- Sponsor
- University of Michigan
- Primary completion
- Nov 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Comparision of the Buproprion Area Under the Concentration Time Curve (AUC) From Time 0 to 96 Hours by Type of Formulation and Dosage |
469; 667; 706; 1002; 740; 1356 | — |
| SECONDARY Comparision of the Buproprion Maximum Concentration (Cmax) by Type of Formulation and Dosage |
93; 136; 61; 78; 61; 111 | — |
Summary
The objectives of this project are to determine if the bioavailability and release pattern of bupropion HCl products differ and if the genotype of the metabolic enzymes affects the saturation of intestinal enzymes with different dose strengths within one product line. Findings from this project will help the FDA Center for Drug Evaluation and Research's (CDER) Office of Generic Drugs improve policy development and review practice in the future for similar products, e.g. extended release oral drug products being metabolized in the gut wall and having multiple strengths.
Aim 1: To compare the pharmacokinetics of bupropion and its metabolites in plasma in healthy individuals when they ingest different strengths of bupropion (75-300 mg) with variable release profiles (IR vs XL vs SR) in GI tract.
Working hypothesis: Variation in release rate and mechanism of bupropion formulations in gastrointestinal (GI) tract will impact metabolism and saturation of bupropion in GI tract, which will generate different concentration of bupropion and its metabolites in plasma.
Aim 2: To investigate pharmacogenomics of CYP 2B6 that influences metabolism, saturation, and pharmacokinetics of bupropion
Working hypothesis: The gain of function of CYP2B6 variants (allele *4 and *22) in patients will increase the metabolism of bupropion in the GI tract and liver, reduce both local concentration and plasma concentration of bupropion, and thus cause non-bioequivalence when bupropion is released earlier in GI tract
Eligibility Criteria
Inclusion Criteria
- Healthy volunteers 25 to 55 years old.
- Volunteers have a Body Mass Index (BMI), calculated from the ratio of height and weight, within a range of 18.5 to 35.
- Willing to be medication and supplement free 2 weeks prior to beginning study, and throughout the study. All forms of birth control are okay.
Exclusion Criteria
- Individuals unwilling or unable to comply with the study protocol (e.g. unable to remain medication or supplement free during the study).
- Individuals unwilling or unable to take bupropion or have an allergy to bupropion
- Any medical or surgical conditions which might significantly alter bupropion absorption (e.g., history of malabsorption, liver disease, gastric bypass surgery )
- Individuals with a history of psychiatric or neurological illness, including seizure disorders
- Nicotine dependence
- Alcohol dependence
- Pregnant or nursing women
Data sourced from ClinicalTrials.gov (NCT02078180). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.